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Abstract
Introduction Phosphorylated Akt (P-Akt) is an attractive
molecular target because it contributes to the development of
breast cancer and confers resistance to conventional therapies.
Akt also serves as a signalling intermediate for receptors such
as human epidermal growth factor receptor (HER)-2, which is
overexpressed in 30% of breast cancers; therefore, inhibitors to
this pathway are being sought. New celecoxib analogues
reportedly inhibit P-Akt in prostate cancer cells. We therefore
examined the potential of these compounds in the treatment of
breast cancer. The analogues were characterized in MDA-MB-
453 cells because they overexpress HER-2 and have very high
levels of P-Akt.
Methods To evaluate the effect of the celecoxib analogues,
immunoblotting was used to identify changes in the
phosphorylation of Akt and its downstream substrates glycogen
synthase kinase (GSK) and 4E binding protein (4EBP-1). In vitro
kinase assays were then used to assess the effect of the drugs
on Akt activity. Cell death was evaluated by poly(ADP-ribose)
polymerase cleavage, nucleosomal fragmentation and MTS
assays. Finally, tumour tissue microarrays were screened for P-
Akt and HER-2 expression.
Results OSU-03012 and OSU-O3013 inhibited P-Akt and its
downstream signalling through 4EBP-1 and GSK at
concentrations well below that of celecoxib. Disruption of P-Akt
was followed by induction of apoptosis and more than 90% cell
death. We also noted that the cytotoxicity of the celecoxib
analogues was not significantly affected by serum. In contrast,
the presence of 5% serum protected cells from celecoxib
induced death. Thus, the structural modification of the celecoxib
analogues increased P-Akt inhibition and enhanced the
bioavailability of the drugs in vitro. To assess how many patients
may potentially benefit from such drugs we screened tumour
tissue microarrays. P-Akt was highly activated in 58% (225/
390) of cases, whereas it was only similarly expressed in 35%
(9/26) of normal breast tissues. Furthermore, HER-2 positive
tumours expressed high levels of P-Akt (P < 0.01), supporting
in vitro signal transduction.
Conclusion We determined that Celecoxib analogues are
potent inhibitors of P-Akt signalling and kill breast cancer cells
that overexpress HER-2. We also defined an association
between HER-2 and P-Akt in primary breast tissues, suggesting
that these inhibitors may benefit patients in need of new
treatment options.
Introduction
Receptor tyrosine kinases (RTKs) are commonly overex-
pressed in breast cancer, in which they promote tumour
growth and metastasis. For example, insulin-like growth factor
(IGF)-1 receptor is an RTK that is overexpressed in about 70%
of breast cancers [1,2]. It is fundamentally linked to malignant
transformation in vitro and in vivo [3]. IGF-1 receptor is also
important for breast cancer invasion and metastasis [4].
Akt-DN = Akt dominant negative; 4EBP-1 = 4E binding protein-1; GSK = glycogen synthase kinase; HER = human epidermal growth factor receptor; 
IGF-1 = insulin-like growth factor-1; MAPK = mitogen-activated protein kinase; P-Akt = phosphorylated Akt; PDK = phosphoinositide-dependent 
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Human epidermal growth factor receptor (HER)-2 is yet
another important RTK that is overexpressed in 25–30% of
invasive ductal breast carcinomas and is associated with poor
patient prognosis and increased risk for recurrence [5]. Trans-
genic mouse models show that HER-2 promotes the develop-
ment of mammary tumours [6]. Armed with this knowledge, it
would appear that finding a convergence point between IGF-
1 receptor and HER-2 would provide a new way to target
treatment.
A common feature of IGF-1 receptor and HER-2 is signalling
through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
[7]. These RTKs activate PI3K, which then catalyzes the pro-
duction of lipid molecules, including phosphatidylinositol-
3,4,5-triphosphate [8]. The phosphatidylinositol-3,4,5-triphos-
phate lipids trigger the attachment of Akt to the plasma mem-
brane, where it subsequently becomes phosphorylated at two
key sites, threonine 308 and serine 473, resulting in its full
activation. Threonine 308 is phosphorylated by phosphoi-
nositide-dependent kinase (PDK)-1, whereas the mechanism
of phosphorylation at serine 473 is a little more controversial.
There are several theories to explain serine 473 phosphoryla-
tion, including the action of integrin-linked kinase, autophos-
phorylation, or an as yet unidentified PDK-2 [9]. Once Akt is
fully activated it dissociates from the plasma membrane and
proceeds to phosphorylate both cytoplasmic and nuclear tar-
get proteins, notably glycogen synthase kinase (GSK)-3β
[10], p27Kip [11], mammalian target of rapamycin [12] and
forkhead transcription factors [13]. The diverse targets of
phosphorylated Akt (P-Akt) regulate proliferation, invasion and
evasion of apoptosis. Thus, Akt is a major convergence point
for RTK signalling in breast cancer, and so inhibiting it could
provide a new therapeutic avenue.
Akt has become a favoured second messenger from a thera-
peutic standpoint because numerous studies point toward it
as a central molecule in the development of cancer. Evidence
from experimental models suggests that Akt is a key regulator
of tumour development and progression. There are three iso-
forms of Akt (Akt1, Akt2 and Akt3), which exhibit 80% amino
acid sequence homology. The overexpression of each of these
isoforms leads to malignant transformation (for review, see Hill
and Hemmings [14]).
Transgenic mouse models have been instrumental in address-
ing the role of Akt in mammary tumour development. For exam-
ple, mammary tumours that develop from HER-2 transgenic
mice clearly overexpress P-Akt [15]. One then questions
whether P-Akt truly facilitates the development of the tumours.
Hutchinson and coworkers [15] addressed this by engineer-
ing bitransgenic mice expressing both HER-2 and constitu-
tively activated Akt1 in the mammary gland. When Akt1 was
constitutively expressed the mice developed tumours at a
much faster rate than in those that only expressed HER-2.
Thus, activated Akt1 plays a functional role in promoting the
development of HER-2 positive mammary tumours. Impor-
tantly, analysis of primary tumour tissues shows that Akt1 is
frequently expressed and highly activated in patients [16].
Akt1 kinase activity is significantly increased in approximately
40–50% of tumour samples from patients with breast (19/50
cases), ovary (11/28 cases) and prostate cancer (16/30
cases) relative to normal tissue [16]. In addition to its role in
cancer development, Akt also promotes the survival of tumour
cells when confronted with chemotherapeutics and radiation.
For example, in breast cancer cells expression of constitutively
active Akt1 reduced the ability of doxorubicin [17] or ionizing
radiation [18] to induce apoptosis. On the other hand, the
PI3K inhibitor Ly294002 or a dominant-negative Akt1 sensi-
tized cancer cells to chemotherapy [17]. These data suggest
that inhibiting P-Akt signalling in tumours could have important
therapeutic applications.
There is intense interest in targeting RTKs and signal trans-
duction intermediates such as Akt for the treatment of cancer
[19]. One approach to inhibiting P-Akt is to target upstream
activators of this pathway. For example, patients with tumours
expressing HER-2 can be treated with herceptin, a mono-
clonal antibody that blocks the activation of the receptor [20]
and subsequently inhibits Akt phosphorylation [21]. However,
fewer than 30% of patients treated with herceptin initially
respond [22]. Within that population of patients who initially
respond to herceptin, some subsequently develop resistance
[22]. A second approach is to inhibit Akt directly. However, no
Akt inhibitors are available to patients, although the proof of
principle was elegantly provided in a study using an Akt dom-
inant negative (Akt-DN) inhibitor [23]. Targeted disruption of
Akt by Akt-DN inhibited the growth of the breast cancer cell
lines ZR75-1 and MDA-MB-453 in vitro. The Akt-DN also
caused the cells to undergo apoptosis. Adenoviral mediated
delivery of Akt-DN also had an impressive antitumour effect in
vivo. That study provided the first evidence that targeted dis-
ruption of Akt induces apoptosis and suppresses tumour for-
mation in mice. Thus, there is growing interest in the discovery
of Akt inhibitors. Potential future drug candidates include
phosphatidylinositol analogues that bind specifically to the PH
domain of Akt and have been shown to inhibit its phosphoryla-
tion in cancer cells [24]. A novel Akt inhibitor was also recently
identified from the National Cancer Institute Diversity Set, and
preclinical evidence [25] is promising. The inhibitor termed
API-2 is a tricyclic nucleoside that selectively kills cancer cells
that express high levels of activated Akt [25].
One of the newest classes of Akt inhibitors to be developed
are those derived from the common anti-inflammatory drug
celecoxib. Initially, it was thought that celecoxib would be a
good inhibitor of Akt [26]. However, it was realized that the
celecoxib concentrations achievable in patients were of the
order of 3 µmol/l [27], whereas 50 µmol/l or greater is
required to inhibit Akt activation in prostate [28] and breast
cancer cells (Kucab and coworkers, unpublished data).Available online http://breast-cancer-research.com/content/7/5/R796
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Nonetheless, the observation that celecoxib inhibited P-Akt
set the course for the development of analogues that optimally
disrupt this pathway at lower concentrations. New celecoxib
analogues have since been developed that are superior inhib-
itors of Akt phosphorylation [29]. The compounds referred to
as OSU03012 and OSU03013 inhibited PDK-1 kinase activ-
ity in vitro (50% inhibitory concentration 2–5 µmol/l) and pre-
vented Akt phosphorylation in prostate cancer cells at 1–10
µmol/l. Upon longer exposure, these inhibitors induce apopto-
sis in PC-3 cells. As a part of the Rapid Access to Preventive
Intervention Development (RAPID) programme at the US
National Cancer Institute [30], a panel of 60 cancer cells lines
were screened for response to OSU03012 and OSU03013.
It was determined that the compounds were potent inhibitors
of tumour cell growth, with an average 50% inhibitory concen-
tration of about 1–2 µmol/l [29]. OSU03012 has also been
given orally at a dose of 200 mg/kg for 1 month without overt
signs of toxicity as part of the RAPID program (Chen and cow-
orkers, unpublished data). Characterization of the celecoxib
analogues thus far indicates that they could be very useful for
safely treating many types of cancer.
We therefore further explored the promise of these celecoxib
analogues for the treatment of breast cancer. An extensive
study of these analogues has not previously been performed
in models of breast cancer. We were also curious as to
whether serum proteins attenuated the cytotoxic effect of the
new analogues as they do with celecoxib [31]. The com-
pounds were evaluated in a HER-2 overexpressing breast can-
cer cell line, namely MDA-MB-453, which is well characterized
for having very high levels of P-Akt. We report herein that both
of the celecoxib analogues inhibited Akt phosphorylation and
Akt kinase activity. The compounds also inhibited phosphor-
ylation of substrates downstream of Akt (GSK and 4EBP-1).
Furthermore, OSU-03012 and OSU-03013 initiated the
apoptotic pathway, resulting in under 90% cell viability within
24 hours. We then addressed how often Akt is activated in pri-
mary tumours to estimate the number of patients that might
benefit from these small molecule inhibitors. We determined
that P-Akt was moderately to highly expressed in 58% of pri-
mary tumours, suggesting that these inhibitors could poten-
tially be used to treat a substantial number of patients.
Furthermore, we found that Akt was commonly activated in
tumours that overexpress HER-2. These data therefore pro-
vide evidence to support further preclinical development of
celecoxib analogues for the treatment of breast cancer, partic-
ularly in cases in which HER-2 is overexpressed.
Materials and methods
Effect of celecoxib analogues on Akt signalling and 
apoptosis
The breast cancer cell lines (MDA-MB-453, MCF-7, T47D,
MDA-MB-231 and HBL100) were obtained from the Ameri-
can Tissue Culture Collection (Manassas, VA, USA). The
184htrt cells were a gift from Dr J Carl Barrett (National Can-
cer Institute, Bethesda, MA, USA). All of the experiments were
performed in the presence of 5% foetal calf serum, RPMI-
1640, with the exception of the 184htrt cells, which were
grown as previously described [32]. The celecoxib analogues
were synthesized as previously described by us [29].
Ly294002 was purchased from Sigma (St. Louis, MO, USA)
and celecoxib was obtained from Pharmacia (St Louise, MO,
USA). All compounds were dissolved in dimethyl sulphoxide.
To study the effect of the inhibitors on signal transduction, the
cells were treated with either the PI3K/Akt inhibitor Ly294002
(30 µmol/l), or OSU03012 or OSU03013 inhibitor, each at 5
and 10 µmol/l for 2 hours or at later times points, as indicated.
Comparisons were also made to the parent compound,
celecoxib, at concentrations of 50 µmol/l and 75 µmol/l.
Whole cell extracts were prepared in accordance with the pro-
tocol for P-Akt detection by Cell Signaling Technologies (CST
Beverly, MA, USA). All antibodies were purchases from CST
unless otherwise indicated. P-AKTser473, P-Aktthr308, total AKT,
P-4EBP-1, P-S6, P-Erk, total Erk, P-MK2, MK2, P-GSK
(Upstate Biotechnology Inc, Lake Placid, NY, USA) and actin
(Santa Cruz Biotechnology, CA, USA) were detected by ana-
lyzing 50 µg total protein separated on a 12% acrylamide gel.
Akt kinase activity was assessed using a modified assay. Non-
radioactive Akt kinase assays were performed using a protocol
modified from that of Cell Signaling Technologies. In brief, 500
µg protein, from cells treated as described above, were immu-
noprecipitated with the 5G3 pan-Akt antibody (CST) over-
night at 4°C. The following day the Akt–antibody complexes
were incubated with protein G coated agarose beads. The
immunoprecipitated complexes were washed and then incu-
bated for 30 minutes at 30°C in kinase buffer with 1 µg of
recombinant GSK-3 protein (CST) and 200 µmol/l ATP. To
stop the reaction, 15 µl of 4× SDS sample buffer with β -mer-
captoethanol was added. The assays were boiled for 5 min
and then one-third of each reaction was separated on a 12%
acrylamide gel and immunoblotted. The blots were analyzed
using antibodies to P-GSK-3 protein, as well as total recom-
binant GSK-3 and total Akt.
In order to assess the effect of the compounds on apoptosis,
the MDA-MB-453 cells were treated with Ly294002,
celecoxib, or the analogues at the indicated concentrations for
12 or 24 hours and poly(ADP-ribose) polymerase (CST) cleav-
age was examined in the treated cells by immunoblotting. Cell
extracts were also subjected to the Cell Death Detection
Assay according to the manufacturer's instructions (Roche
Diagnostics, Laval, QC, Canada). The viability of MDA-MB-
453 was determined 24 hours after exposure to celecoxib, the
analogues, or Ly294002 using the Celltiter 96 Aqueous cell
proliferation/survival assay (Promega, Madison WI, USA), as
previously described [33]. The influence of serum proteins
was also examined. The MDA-MB-453 cells were treated with
the test compounds as indicated in either 5% foetal bovineBreast Cancer Research    Vol 7 No 5    Kucab et al.
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serum/RPMI or 0.1% foetal bovine serum/RPMI, and cytotox-
icity was evaluated 24 hours later using the MTT assay.
Examination of phosphorylated Akt in primary breast 
tissues
For construction of the tumour tissue microarray (TMA), 481
primary breast cancer samples were obtained from archival
cases at Vancouver General Hospital dating between 1974
and 1995. Patient information and tumour pathology are sum-
marized in Additional file 1. Anonymous coding was used to
protect patient rights and the samples were procured in
accordance with the guidelines established by the Vancouver
General Hospital. Tumour samples were taken before initiation
of cancer treatment, and were formalin fixed and embedded in
paraffin. The TMA was constructed as previously described by
us [1].
For detection of P-Akt, the tissues underwent antigen retrieval
by incubating the slides for 30 min in 10 mmol/l citrate buffer
(pH 6.0) at 60–90°C in a vegetable steamer. Endogenous per-
oxidases were quenched by incubating the sections for 10 min
in 3% H2O2. Additionally, nonspecific interactions were
blocked for 30 min using a non-serum-blocking reagent
(DAKO, Denmark), followed by 20 min with an avidin/biotin
blocking solution (DAKO, Carpenteria, Ca, USA). The primary
antibody (Phospho-AKTS473 IHC Specific; CST) was diluted
1:250 with a 1% bovine serum albumin solution, applied to the
sides and incubated overnight at 4°C. For signal amplification,
we then used the LSAB+ System (DAKO), which involved
incubation with a biotinylated secondary antibody followed by
streptavidin treatment. P-Akt was visualized by addition of
NovaRed substrate (Vector Laboratories, Burlingame, CA,
USA) and the sections were counter-stained with haematoxy-
lin. Additionally, a negative control reaction with no primary
antibody was performed for each slide in parallel.
The scoring system for P-Akt expression was as follows: 0 =
negative, 1 = weak, 2 = moderate and 3 = high staining inten-
sity. Of the 481 cases on the array, 438 contained invasive
carcinoma and the characteristics of these patients are
described in Table 1. A total of 390 invasive carcinoma cases
were interpretable for P-Akt expression. In most cases, P-Akt
expression was detected primarily in the cytoplasm, although
nuclear staining was occasionally observed. The majority of P-
Akt was predominantly expressed in the tumour epithelial cells,
although there was also notable staining of the endothelial
cells. P-Akt was not expressed in the stroma. To assess P-Akt
staining in normal breast tissue, 26 samples were obtained
from patients who underwent reduction mammoplasties at
Vancouver General Hospital from 2000 to 2001. The tissues
were formalin fixed and paraffin embedded. One section of
each sample was stained with haematoxylin and eosin and
then assessed by a pathologist to ensure presence of normal
breast epithelium. P-Akt immunohistochemistry was per-
formed on the normal tissues as described above for the
TMAs. Raw scores for P-Akt expression were entered into a
standardized electronic spreadsheet (Excel for Windows,
Microsoft, Redmond, WA, USA), processed using Deconvo-
luter software designed for management of TMA data, and
then analyzed using the SPSS for Windows statistical soft-
ware package (SPSS version 11; SPSS, Chicago, IL). The dif-
ference in P-Akt expression between normal and tumour
breast tissue was calculated using χ 2 analysis. HER-2 R was
stained with an antibody designated A485 (Dako) at a dilution
of 1:500 and detected using the LSAB+ System.
Results
Celecoxib analogues disrupt Akt signalling in breast 
cancer cells and induce apoptosis
We screened a panel of breast cell lines for P-Akt to find the
one with the highest levels. Our panel included the preneo-
plastic cell line 184htrt and the cancer cell lines T47D, MCF-
7, MDA-MB-231 and MDA-MB-453. The MDA-MB-453 cells
expressed the highest level of P-Akt, and therefore they were
extensively used to characterize the effect of the celecoxib
analogues on the Akt pathway (Fig. 1a). This cell line also
expressed the highest level of HER-2 (Fig. 1b).
To examine the potential effect of the inhibitors, the MDA-MB-
453 cells were treated for 2 hours with DMSO, Ly294002 (30
µmol/l), OSU-03012 (5 or 10 µmol/l) or OSU-03013 (5 or 10
µmol/l) and compared with celecoxib treated cells (50 or 75
µmol/l). The celecoxib analogues suppressed phosphorylation
of Akt at threonine 308 and serine 473, whereas celecoxib did
not (Fig. 2a). These data indicated that Akt kinase activity
should be inhibited by the celecoxib analogues. In support of
this, we determined that the analogues inhibited phosphoryla-
tion of the Akt substrates GSK-3β  and 4E-BP1 (Fig. 2a). Sim-
Table 1
Correlation between P-Akt and HER-2 proteins in primary breast tumours
Negative (P-Akt 0,1) Positive (P-Akt 2,3) Total
Negative (HER2 0,1; counted/expected) 111/100.2 130/140.8 241
Positive (HER2 2,3; counted/expected) 32/42.8 71/60.2 103
Total 143 201 344
A total of 344 invasive ductal carcinomas were examined for expression of phospharylated Akt (P-Akt) and human epidermal growth factor 
receptor (HER)-2. A binary scoring system (0,1 versus 2,3) was used to compare staining between samples. Patients who overexpressed HER-2 
were more likely to express P-Akt also. Statistical analysis was derived through the χ 2 test (P < 0.01).Available online http://breast-cancer-research.com/content/7/5/R796
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ilarly, the celecoxib analogues inhibited P-Akt in the T47D cells
(Fig. 2b). Kinase assays were then performed on the MDA-
MB-453 cells to provide direct evidence that Akt activity was
lost. Each of the celecoxib analogues markedly suppressed
Akt kinase activity, similar to that with the PI3K/Akt inhibitor
Ly294002 (Fig. 2c).
The off-target effects of the inhibitors were then examined by
focusing on the mitogen-activated protein kinase (MAPK) and
p38 pathways. OSU03012 did not inhibit signal transduction
through the MAPK pathway, based on a lack of P-Erk inhibition
(Fig. 2d). Similar results were found for Ly294002. In contrast,
OSU03013 inhibited P-Erk at 4 hours (Fig. 2d, lane 8) and
more so at 6 hours (Fig. 2d, lane 12). This was an important
finding because it indicated that OSU03012 specifically inhib-
ited the Akt pathway. OSU03013 on the other hand inhibited
both the Akt and MAPK pathways at the later time points. To
complete this portion of the study, the potential effect of the
compounds was examined in the context of the p38 pathway
by monitoring P-MAPK activated protein kinase-2. The latter
was not inhibited by OSU03012, OSU03013, or Ly294002
(Fig. 2d). Thus, the celecoxib analogues are potent inhibitors
of the Akt pathway in HER-2 over-expressing breast cancer
cells; however, OSU03012 was more specific than
OSU03013.
Akt plays a central role in preventing apoptosis, and therefore
we investigated the potential for the celecoxib analogues to
trigger programmed cell death. Subsequent to the inhibition of
Akt activity, we observed a significant increase in poly(ADP-
ribose) polymerase cleavage 12 and 24 hours later, indicating
that the cells were undergoing apoptosis (Fig. 3a). This was
consistent with nucleosomal fragmentation (Fig. 3b). We
therefore concluded that the cells were undergoing apoptosis
following drug treatment. The fate of the cells was followed to
24 hours, at which time cell viability was assessed.
OSU03012 and OSU03013 killed the MDA-MB-453 cells in
a dose dependent manner (Fig. 3c). There was a more than
90% reduction in viability with 10 µmol/l of each of the com-
pounds. In contrast, the parent compound celecoxib had a
similar effect on viability at 100 µmol/l. These studies were
then extended to include the T47D breast cancer cells, and
they responded in a similar manner (Fig. 3d).
It was noted that although Ly294002 inhibits P-Akt, its effect
on cell viability was not as robust as that of OSU03012. To
elucidate why this may be, we treated the cells with Ly294002
over periods of 2, 4, 6 and 24 hours to evaluate the possibility
that it may not be stable in an aqueous solution and therefore
loses its ability to inhibit P-Akt. We noted that after 6 hours the
ability of Ly294002 to inhibit P-Akt began to diminish. Further-
more, by 24 hours Ly294002 only inhibited P-Akt by about
50% (Fig. 3e, top panel). In contrast, P-Akt inhibition was sus-
tained for OSU03012 throughout the time course (Fig. 3g,
bottom panel). It was not possible to measure the effect of
OSU03012 after 24 hours because of the cytotoxic effect on
the cells. Thus, we determined that Ly294002 was unable to
sustain its inhibitory effect on P-Akt, which could explain why
only 25–30% of the cells died after 24 hours.
The efficacy of anticancer drugs can be perturbed by prob-
lems with serum binding, and this often results in attenuated
cellular effects. Therefore, we compared the cytotoxic effect of
OSU03012 and OSU03013 in high (5%) verses low (0.1%)
serum. This was done to ascertain whether serum had a pro-
tective effect against the celecoxib analogues. Up to this point,
all of the experiments were performed in 5% foetal bovine
serum/RPMI 1640 containing media, and therefore
comparisons were made with cells treated in 0.1% fetal bovine
serum/RPMI 1640. Serum had a remarkable protective effect
against celecoxib (Fig. 4). In contrast, the serum had little
effect on how well the celecoxib analogues killed the cells.
These data suggest that altering the chemical structure of
Figure 1
Examination of P-Akt and HER-2 levels in a panel of breast cancer cell  lines Examination of P-Akt and HER-2 levels in a panel of breast cancer cell 
lines. (a) Proteins were isolated from cells growing in log phase and the 
levels of phosphorylated Akt (P-Akt) were then assessed using antibod-
ies to serine 473 and threonine 308. MDA-MB-453 cells expressed the 
highest levels of activated Akt relative to the other lines. There were no 
differences in the levels of total Akt with the exception of the preneo-
plastic cell line 184htrt. Actin was detected as a loading control. (b) 
Human epidermal growth factor receptor (HER)-2 protein expression 
was evaluated in a panel of breast cell lines. The MDA-MB-453 and 
T47D cells expressed HER-2 whereas the other cell lines did not.Breast Cancer Research    Vol 7 No 5    Kucab et al.
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celecoxib not only enhanced cell killing but also increased the
bioavailability of the drugs in the presence of serum.
Frequency of phospharylated Akt expression in normal 
and tumor breast tissue
In order to estimate the proportion of patients that might ben-
efit from inhibitors to P-Akt, we screened breast tumour TMAs.
A description of the patients and the clinicopathological fea-
tures of their tumours are given in Additional file 1. P-Akt
expression was moderately to highly expressed in 58% (221/
390) of the tumours. The distribution of P-Akt expression in the
390 tumours was as follows: no staining, 43/390 (11%); weak
staining, 122/390 (31%); moderate staining, 120/390 (31%);
and strong staining, 105/390 (27%; Fig. 5a–d, respectively).
P-Akt was predominantly expressed in epithelial cells and was
noted in endothelial cells, but it was not expressed in the
stroma. P-Akt was highly expressed in both oestrogen recep-
tor positive and negative cases. There was no significant dif-
ference (P = 0.5839) in overall survival between patients who
expressed high levels of P-Akt and those who expressed low
levels of the activated protein. We also evaluated the
relationship of P-Akt expression with other clinicopathologic
Figure 2
Impact of signal transduction inhibitors on Akt signalling Impact of signal transduction inhibitors on Akt signalling. (a) The MDA-MB-453 cells were treated for 2 hours with Ly294002 (30 µmol/l), 
OSU03012, OSU03013 (5 or 10 µmol/l), or celecoxib (50 or 75 µmol/l). The Celecoxib analogues inhibited Akt phosphorylation at both threonine 
308 and serine 473. Phosphorylation of the Akt substrates glycogen synthase kinase (GSK) and 4E binding protein (4EBP)-1 was subsequently 
attenuated. In contrast, celecoxib did not have an inhibitory effect. Ly294002 inhibited signal transduction through Akt, as expected. Total Akt and 
actin were unaffected by exposure to the signalling inhibitors. (b) T47D cells were also exposed to the drugs as described above and evaluated for 
phosphorylated Akt (P-Akt) using antibodies to Ser473 and Thr308. Total Akt was included as a control for loading. (c) Cells were treated as above 
and Akt kinase was measured against the substrate GSK. Each of the celecoxib analogues inhibited Akt kinase activity. The degree of inhibition was 
similar to that with Ly294002. There was minimal nonspecific kinase activity in the absence of Akt based on the IgG control. Total Akt was evaluated 
as a loading control to confirm that the loss of activity was not due to differences in experimental conditions. (d) The MDA-MB-453 cells were 
treated for 2, 4, or 6 hours with dimethyl sulphoxide (DMSO), Ly294002 (30 µmol/l), OSU03012 (10 µmol/l), or OSU03013 (10 µmol/l) and 
probed for P-Erk1/2, total Erk, P-MK2, total MK2 and actin.Available online http://breast-cancer-research.com/content/7/5/R796
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Figure 3
Effect of the Celecoxib analogues on apoptosis induction Effect of the Celecoxib analogues on apoptosis induction. To follow the fate of the cells upon Akt inhibition, indicators of apoptosis were temporally 
measured. Poly(ADP-ribose) polymerase (PARP) cleavage and nucleosomal fragmentation were measured after 12 and 24 hours. The cells were 
treated with Ly294002 (30 µmol/l), Celecoxib (50 or 100 µmol/l), OSU03012 (5, 7.5, or 10 µmol/l), or OSU03013 (5, 7.5, or 10 µmol/l) and then 
the cell pellets were split for PARP and nucleosomal cleavage. (a) There was a dose dependent increase in PARP cleavage on treatment with 
OSU03012 and OSU03013 at both 12 and 24 hours. LY294002 similarly induced PARP cleavage but to a lesser extent. Celecoxib at 50 µmol/l 
did not have sustained effects on PARP cleavage, whereas the high dose of celecoxib (100 µmol/l) did. (b) The induction of apoptosis was second-
arily analyzed by nucleosomal fragmentation. There was a dose dependent increase in nucleosomal fragmentation upon treatment with increasing 
concentration of either OSU03012 or OSU03013. Likewise, Ly294002 induced fragmentation of the nucleosomes at both time points. Celecoxib at 
50 µmol/l did not have such an effect. In contrast, high dose celecoxib did stimulate apoptosis. Each treatment was conducted in replicates of six on 
two difference occasions. (c) Impact of signal transduction inhibitors on cell survival. The MDA-MB-453 cells were exposed to Ly294002 (30 µmol/
l), celecoxib, OSU03012, and OSU03013 at the indicated concentrations and cell viability was assessed 24 hours later. OSU03012 and 
OSU03013 killed more than 90% of the cells with 10 µmol/l of the respective inhibitors. Celecoxib at 100 µmol/l had a similar effect, but celecoxib 
at 50 µmol/l was not effective at reducing cell viability. This screen was conducted in replicates of four in three separate experiments. (d) The T47D 
cells similarly responded to the celecoxib analogues based on cell survival. Each experiment was performed in replicates of six on three separate 
occasions. (e) MDA-MB-453 cells were treated for 2, 4, 6, or 24 hours with Ly294002 and P-Akt was measured (top panel). A comparison was 
made with the MDA-MB-453 cells exposed to OSU03012 (10 µmol/l) for 2, 4, or 6 hours. Total Akt was measured as a control for sample input.Breast Cancer Research    Vol 7 No 5    Kucab et al.
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variables, such as grade, lymph node status and histology, but
we found no significant correlations (data not shown). This is
most likely because we were unable to define the patient pop-
ulation based on treatment.
Comparisons were then made between normal and neoplastic
tissues because we noted that in some instances the adjacent
normal ducts expressed less P-Akt (Fig. 5e, broken arrow)
compared with the tumour (Fig. 5e, solid arrow). Because the
cores only represent a small amount of the tumour tissue, nor-
mal ducts were often not present. We obtained 26 normal
breast tissue samples from reduction mammoplasties to exam-
ine P-Akt. In some instances, P-Akt was not expressed (Fig. 5f)
whereas in others it was detectable (Fig. 5g). Overall, we
determined that P-Akt was moderately to highly expressed in
only 35% (9/26) of cases. We then determined that P-Akt
more likely to be activated in tumours than in normal breast tis-
sue by χ 2 analysis (P ≤  0.025). Thus, inhibitors to this pathway
would hopefully affect the tumour tissue and cause few side
effects in surrounding normal tissue. We also noted expres-
sion of activated Akt in endothelial cells surrounding tumours
(Fig. 5h). Thus, OSU03012 and OSU03013 could potentially
inhibit P-Akt in tumours as well as in the surrounding endothe-
lial cells.
Finally, in attempt to elucidate why Akt may be activated in the
tumours, we stained the tissues for HER-2 expression. Tumors
that expressed high levels of HER-2 were much more likely to
express activated Akt (P  < 0.01) than were those that
expressed low levels of the receptor (Table 1). Therefore, in
this cohort of patients HER-2 overexpression was positively
related to activated Akt, further supporting in vitro models of
Figure 4
Effect of serum on the cytotoxicity of celecoxib and its analogues Effect of serum on the cytotoxicity of celecoxib and its analogues. MDA-MB-453 cells were treated with dimethyl sulphoxide (DMSO), Ly294002, 
celecoxib, OSU03012, or OSU03013 in either 5% foetal bovine serum/RPMI 1640 or 0.1% foetal bovine serum/RPMI 1640. Cell survival was 
measured 24 hours later using the MTT assay. Each of the treatments were tested in replicates of four and repeated twice.
Figure 5
Phosphorylated Akt expression in tumour and normal tissues of the breast Phosphorylated Akt expression in tumour and normal tissues of the breast. (a-d) Phosphorylated Akt (P-Akt) staining of invasive ductal carcinomas 
(IDCs) of the breast ranging from undetectable to intense staining. The scoring system was from 0 to 3 and examples of such are represented in 
panels a-d, respectively. (e) Normal ducts (dashed arrow) adjacent to the IDC (solid arrow) expressed appreciably less P-Akt. (f) Likewise, P-Akt 
staining was weak when whole sections of normal breast tissue were stained. (g) However, some cases of normal breast tissues stained more 
intensely for P-Akt. (h) It was also noted that P-Akt was present in endothelial cells surrounding the tumours. Original magnifications: panels a-g, 
200×; panel h, 400×.Available online http://breast-cancer-research.com/content/7/5/R796
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signal transduction. Together, these data show that P-Akt is
frequently activated in primary breast cancers, indicating that
small molecule inhibitors targeting this pathway may be useful
for treating this disease.
Discussion
In this study, we determined that OSU03012 and OSU03013
are potent inhibitors of the Akt signalling pathway, which are
effective at inducing apoptosis in a breast cancer cell line that
expresses high levels of HER-2. Alternatively, celecoxib was
not particularly effective at inhibiting Akt or killing the MDA-
MB-453 cells. Thus, the new celecoxib analogues are much
better than the parent compound at inhibiting the Akt pathway.
Between the two inhibitors, it appeared that OSU03012 was
more specific for inhibiting the Akt pathway than was
OSU03013. We also noted that the celecoxib analogues
were just as effective in high serum as they were in low serum.
This is in contrast to the protective effect that serum had on
celecoxib. Our data is consistent with the protection afforded
by serum when pancreatic cells were treated with celecoxib
(50 µmol/l) [31].
Thus, it appears that structural modification of celecoxib
resulted not only in increased P-Akt inhibition but also in
enhanced bioavailability, at least in vitro. This is important to
us because we move toward the development of Akt inhibitors
that could be taken orally. For example, we previously reported
that the oral administration of the celecoxib derivative DMC
(4- [5-(2,5-dimethylphenyl)-3 trifluoromethyl-1H-pyrazol-1-yl]-
benzene-sulfonamide) resulted in inhibition of P-Akt and ulti-
mately suppressed development of prostate tumours [34].
This compound is structurally related to OSU03012 and
OSU03013, and therefore we expect them also to be amena-
ble to oral administration. In a recent study, OSU03012 (100
mg/kg per day) was given orally to mice bearing prostate
tumours, and the intratumoural concentrations of the drug
were in excess of 15 µmol/l, which coincided with tumour
regression (Kulp S. personal communication). The mice toler-
ated the drug very well without weight loss. These data are
important because our work indicates that we only need 5–10
µmol/l OSU03012 to kill highly aggressive breast cancer cells
in vitro. Thus, if we are able to establish an intratumoural con-
centration in excess of 15 µmol/l, then it is very likely that this
compound will have a cytotoxic effect against the MDA-MB-
453 cells when studied in a xenograft model. The lack of overt
toxicity is also striking and will be confirmed in models of
breast cancer. Given these encouraging data, preclinical stud-
ies to this effect are currently underway in our laboratory in
models of breast cancers.
We also determined that P-Akt was expressed in 58% (221/
390 cases) of breast cancers. This represents one of the
largest studies of P-Akt expression in breast cancer to date.
The largest study reported that 49% (331/670) of breast can-
cer cases expressed high P-Akt [35]. Similarly, a smaller study
of 40 patients reported that P-Akt was highly activated in 48%
of breast cancer cases [36]. The prognostic value of P-Akt
appears to depend on the types of tumours analyzed and the
treatment protocol that the patients received. Like Panigrahi
and coworkers [35], we did not find an association between
P-Akt and patient survival. In both cases, P-Akt was examined
in a large cohort of patients (about 670 cases) for whom treat-
ment was not standardized, which could explain the lack of
correlation with survival. In contrast, P-Akt was reported to be
associated with poor overall survival in a subset of lymph node
negative breast cancer patients (n = 99) for whom treatment
was standardized [37]. Likewise, P-Akt predicted poor out-
come among endocrine treated breast cancer patients (n =
93) who participated in a clinical trial using tamoxifen, gosere-
lin, or both agents [38]. In another study [39] P-Akt was not
associated with poor survival in a group of patients that was
part of a controlled clinical trial examining the potential benefit
of chemotherapy. The investigators found that the expression
of P-Akt did not differentiate between chemotherapy respond-
ers and nonresponders. However, P-Akt was associated with
a lack of response to radiotherapy. They concluded that
patients were more likely to benefit from radiotherapy if their
tumours were P-Akt negative.
Regarding P-Akt in normal tissues, we are the first to examine
the frequency of P-Akt in normal breast tissue, in which Akt
was activated in only 35% of cases, as compared with 58% of
tumours. Similar to our study, basal P-Akt is low in normal ovar-
ian surface epithelial cells compared with tumour cell lines
[40]. Normal fibroblasts and colonic epithelial cells also
express relatively little P-Akt compared with tumour cell lines
[23]. It remains unclear what regulates P-Akt expression in nor-
mal ducts. We suspect that it relates to hormonal and/or
growth factor activation of the Pi3K/Akt pathway. In particular,
oestrogen and IGF-1 have been shown to stimulate the phos-
phorylation of Akt and induce its kinase activity in breast can-
cer cells [41]. Because oestrogen and IGF-1 are also present
in the sera of women, it is possible that these mitogens could
induce P-Akt in normal breast epithelial cells. Independent of
this, we found that breast tumours consistently had higher lev-
els of P-Akt. We estimate that breast tumours are twice as
likely to express high levels of P-Akt, providing further rationale
for developing inhibitors of this pathway for the treatment of
cancer. Importantly, tumour cells actually depend on activated
Akt for survival whereas normal cells do not [23]. This was
determined using an adenoviral system that produced an Akt
dominant negative inhibitor.
It could be anticipated that the celecoxib analogues might also
be used in instances where resistance to standard
chemotherapy has developed [42]. There are cases in which
HER-2 overexpressing cells are refractory to herceptin treat-
ment. This was illustrated in a clinical trial in which patients
were recruited based on HER-2 overexpression. It was
somewhat surprising that under 30% of patients responded toBreast Cancer Research    Vol 7 No 5    Kucab et al.
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herceptin even though they qualified for the study based on
HER-2 overexpression. Patients with amplified HER-2 had a
34% response rate whereas only 7% responded without
amplification [22]. This study also pointed out that only
patients with tumours that stained 3+ (n  = 84 patients)
responded to the drug whereas those staining 2+ (n = 27
patients) did not. The patients who did not respond were
described as having tumours with moderate overexpression
(2+) and/or that expressed HER-2 in the absence of gene
amplification. It is noteworthy that the MDA-MB-453 cell line is
a model for such tumours. They are considered to be moder-
ate HER-2 overexpressing cells (2+) when compared with
SkB-3 (3+) or BT-474 cells (3+), based on western blotting
[43]. Although they overexpress HER-2, they are resistant to
herceptin [43,44]. At this point, the underlying mechanism for
recalcitrance to herceptin is not understood. One possible
explanation for resistance is the high levels of P-Akt [43]. To
examine this in more detail, constitutively activated Akt was
expressed in BT-474 cells, which are known to be sensitive to
Herceptin. However, expression of high P-Akt rendered the
BT-474 cells insensitive to herceptin [43]. This is consistent
with a report showing that that inhibiting P-Akt with Ly294002
enhances the cytotoxic effect of herceptin [17]. Inhibiting P-
Akt with Ly294002 also prevents the anchorage independent
growth of breast cancer cell lines that overexpress HER-2,
such as the MDA-MB-453 cells [45]. A dominant negative
inhibitor of the p85 subunit of Pi3K similarly blocked anchor-
age independent growth, providing further evidence that
selective inhibition of this pathway may be particularly useful
when treating HER-2 overexpressing breast cancers [45].
With respect to this, it seems reasonable that inhibiting the Akt
pathway may be a way to kill breast cancer cells that have
developed herceptin resistance.
Our study indicates that OSU03012 and OSU03013 inhibit
P-Akt and ultimately kill herceptin resistant cells in vitro. This is
timely, given a recent report [46] showing that the parent com-
pound celecoxib did not benefit patients with HER-2 overex-
pressing tumours that were also resistant to herceptin. Thus,
now more than ever there is a need to identify new agents that
can be used to treat patients who have limited therapeutic
options.
Conclusion
In conclusion, celecoxib analogues provide an opportunity to
inhibit P-Akt and ultimately kill breast cancer cells that overex-
press HER-2.
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